Kirkland & Ellis along with British firm Slaughter and May represented U.K.-based GlaxoSmithKline in its new joint venture with Pfizer to form a global consumer healthcare business, Kirkland announced Dec. 19.
Some of Kirkland’s most high-profile M&A names worked on the deal, which creates the world’s biggest supplier of over-the-counter medicines. The 2017 global sales for Pfizer and GSK consumer-health businesses were approximately $12.7 billion combined.
The transaction also paves the way for GSK to split its business between consumer health and prescription drug units.
Kirkland’s team was led by corporate partners Daniel Wolf, Eric Schiele, Claire James, and Patrick ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.